Bevacizumab 5mg/kg Monotherapy – 14 Day
CISplatin, Lomustine and vinCRIStine (CLV) Therapy
Indication
00806
Adult high-risk medulloblastoma or other primitive neuro-ectodermal tumour (PNET)
Procarbazine Lomustine and VinCRIStine (PCV) Therapy
Indication
00379a
Adjuvant treatment of Grade II glioma administered after radiotherapy.
00379b
Palliative treatment for recurrent high grade gliomas.
Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days
Lomustine 130mg/m2 Therapy
Bevacizumab 5mg/kg Monotherapy – 14 Day
CISplatin, Lomustine and vinCRIStine (CLV) Therapy
Indication
00806
Adult high-risk medulloblastoma or other primitive neuro-ectodermal tumour (PNET)
Lomustine and Bevacizumab 7.5mg/kg Therapy
Lomustine and Bevacizumab 5mg/kg Therapy
Temozolomide Recurrent Therapy
Indication
00342a
Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy
Indication
00334a
Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation.
Bevacizumab 5mg/kg Monotherapy – 14 Day
CISplatin, Lomustine and vinCRIStine (CLV) Therapy
Indication
00806
Adult high-risk medulloblastoma or other primitive neuro-ectodermal tumour (PNET)
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years
Indication
00461a
Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide ii